Brokers Set Expectations for Ikena Oncology Q1 Earnings

Ikena Oncology, Inc. (NASDAQ:IKNA) – Analysts at William Blair issued their Q1 2026 earnings per share estimates for Ikena Oncology in a research report issued to clients and investors on Thursday, May 8th. William Blair analyst M. Phipps forecasts that the company will post earnings of ($0.20) per share for the quarter. The consensus estimate for Ikena Oncology’s current full-year earnings is ($0.91) per share. William Blair also issued estimates for Ikena Oncology’s Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.18) EPS and Q4 2026 earnings at ($0.19) EPS.

Ikena Oncology Price Performance

Shares of NASDAQ:IKNA opened at $1.14 on Monday. The business’s fifty day moving average price is $1.23 and its two-hundred day moving average price is $1.46. Ikena Oncology has a fifty-two week low of $0.97 and a fifty-two week high of $1.94. The stock has a market capitalization of $54.77 million, a price-to-earnings ratio of -0.92 and a beta of 0.47.

Ikena Oncology (NASDAQ:IKNA) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.03.

Institutional Trading of Ikena Oncology

A number of large investors have recently bought and sold shares of the stock. XTX Topco Ltd grew its position in Ikena Oncology by 350.6% in the first quarter. XTX Topco Ltd now owns 56,452 shares of the company’s stock valued at $72,000 after acquiring an additional 43,924 shares during the period. BML Capital Management LLC grew its position in Ikena Oncology by 3.5% in the first quarter. BML Capital Management LLC now owns 3,710,803 shares of the company’s stock valued at $4,750,000 after acquiring an additional 124,937 shares during the period. Squarepoint Ops LLC acquired a new position in Ikena Oncology in the fourth quarter worth $72,000. BNP Paribas Financial Markets acquired a new position in Ikena Oncology in the fourth quarter worth $72,000. Finally, Northern Trust Corp boosted its stake in Ikena Oncology by 19.7% in the fourth quarter. Northern Trust Corp now owns 57,565 shares of the company’s stock worth $94,000 after purchasing an additional 9,456 shares in the last quarter. 75.00% of the stock is currently owned by institutional investors.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.